News & Events

News & Events : Press Releases

October 28, 2014

MARSHA FANUCCI NAMED TO FORMA THERAPEUTICS BOARD OF DIRECTORS

WATERTOWN, Mass. – October 28, 2014 – FORMA Therapeutics today announced the appointment of Marsha H. Fanucci, former Senior Vice President and Chief Financial Officer of Millennium Pharmaceuticals to the company’s Board of Directors. Since February 2014, Ms. Fanucci has served as Senior Financial Advisor to FORMA, contributing to strategic and operational financial planning. She will also serve as Chair of FORMA’s Audit Committee.

“Marsha’s qualifications to join FORMA’s Board of Directors and Chair the Audit Committee stem from her record of proven leadership in advancing an investment-stage company to a profitable industry leader and experience in building an organization centered on a foundation of high integrity.”

“Marsha’s exceptional background and expertise in corporate strategy, finance and operations makes her a distinguished addition to our team,” said Steven Tregay, Ph.D., Founder and CEO, FORMA Therapeutics. “Marsha’s qualifications to join FORMA’s Board of Directors and Chair the Audit Committee stem from her record of proven leadership in advancing an investment-stage company to a profitable industry leader and experience in building an organization centered on a foundation of high integrity.”

“I am particularly excited to be joining FORMA’s Board of Directors and contributing to FORMA’s Changing Lives team on their journey of relentless pursuit to discover and develop innovative solutions for patients,” said Ms. Fanucci. “I look forward to assisting in building a fully sustainable, leading biotechnology company.”

From 2000 to 2009, Ms. Fanucci served at Millennium Pharmaceuticals in a number of executive leadership positions, including Chief Financial Officer and Senior Vice President of Strategy, Vice President of Finance and Strategy, and Vice President of Corporate Development and Strategy. During her tenure, Ms. Fanucci directly contributed to a series of strategic processes, advanced investment-stage Millennium to profitability and was instrumental in the acquisition by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was Vice President of Corporate Development and Strategy at Genzyme Corporation and Vice President and Director at Arthur D. Little. Ms. Fanucci serves on the boards of directors of Alnylam Pharmaceuticals, Ironwood Pharmaceuticals and Momenta Pharmaceuticals. Ms. Fanucci received a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University.

About FORMA Therapeutics

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology and other genetically driven therapeutic areas. The company's drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis and protein-protein interactions. Deep biological insight across targets is combined with the company's chemistry expertise and integrated with a world class network of academic investigators, clinical experts and corporate partners to rapidly direct the creation of high quality, innovative drug candidates.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT.

Media Contact

For FORMA Therapeutics
Kari Watson or Charles Liles, +1 781-235-3060
kwatson@macbiocom.com or cliles@macbiocom.com
MacDougall Biomedical Communications